Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients with Stable Heart Failure using Olmesartan

INTERVENTION: Olmesartan 5‐40mg daily, during the study period. Control CONDITION: Chronic Heart Failure PRIMARY OUTCOME: A composite of all‐cause death, nonfatal acute myocardial infarction, nonfatal stroke, and hospital admission due to congestive heart failure. SECONDARY OUTCOME: Secondary outcomes; 1)all‐cause death; 2)cardiovascular death; 3)death due to heart failure; 4)sudden death; 5)acute myocardial infarction; 6)stroke; 7)hospital admission from any cardiovascular reasons; ; Other outcomes; 1)fatal arrhythmia or appropriate ICD discharge; 2)new‐onset diabetes; 3)development of renal failure; 4)new‐onset atrial fibrillation; 5)a need to modify treatment procedures for heart failure; 6)left ventricular ejection fraction; 7)BNP INCLUSION CRITERIA: Patients who meet all of the following criteria. 1)Chronic heart failure patients with NYHA function class II, III, or IV. 2)Patients who have a history of hypertension or those who have antihypertensive medications. 3)Patients who are aged 20 years or older and less than 80 years at the entry. 4)Stable patients who have angiotensin converting enzyme inhibitor and/or beta‐blocker. 5)Patients who do not have angiotensin II receptor blocker.